88 related articles for article (PubMed ID: 3958183)
1. Prognostic role of antibody reactivity to melanoma.
Vlock DR; DerSimonian R; Kirkwood JM
J Clin Invest; 1986 Apr; 77(4):1116-21. PubMed ID: 3958183
[TBL] [Abstract][Full Text] [Related]
2. Incidence of serum antibody reactivity to autologous head and neck cancer cell lines and augmentation of antibody reactivity following acid dissociation and ultrafiltration.
Vlock DR; Scalise D; Schwartz DR; Richter DE; Krause CJ; Baker SR; Carey TE
Cancer Res; 1989 Mar; 49(6):1361-5. PubMed ID: 2924293
[TBL] [Abstract][Full Text] [Related]
3. Serial studies of autologous antibody reactivity to melanoma. Relationship to clinical course and circulating immune complexes.
Vlock DR; Kirkwood JM
J Clin Invest; 1985 Aug; 76(2):849-54. PubMed ID: 3875634
[TBL] [Abstract][Full Text] [Related]
4. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma.
Hsueh EC; Gupta RK; Qi K; Yee R; Leopoldo ZC; Morton DL
Cancer J Sci Am; 1997; 3(6):364-70. PubMed ID: 9403050
[TBL] [Abstract][Full Text] [Related]
5. Augmentation of autologous antibody to human melanoma following acid dissociation and ultrafiltration of serum.
Kirkwood JM; Vlock DR
Cancer Res; 1984 Sep; 44(9):4177-82. PubMed ID: 6744327
[TBL] [Abstract][Full Text] [Related]
6. Endogenous immune response to early- and intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors.
Litvak DA; Gupta RK; Yee R; Wanek LA; Ye W; Morton DL
J Am Coll Surg; 2004 Jan; 198(1):27-35. PubMed ID: 14698308
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of urinary antigen analysis by enzyme-linked immunosorbent assay in melanoma patients.
Gupta RK; Huth JF; Korn EL; Morton DL
Diagn Immunol; 1983; 1(4):303-9. PubMed ID: 6388975
[TBL] [Abstract][Full Text] [Related]
8. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.
Bouwhuis MG; Suciu S; Collette S; Aamdal S; Kruit WH; Bastholt L; Stierner U; Salès F; Patel P; Punt CJ; Hernberg M; Spatz A; ten Hagen TL; Hansson J; Eggermont AM;
J Natl Cancer Inst; 2009 Jun; 101(12):869-77. PubMed ID: 19509353
[TBL] [Abstract][Full Text] [Related]
9. Incidence of antiretinal antibodies in melanoma: screening of 77 serum samples from 51 patients with American Joint Committee on Cancer stage I-IV.
Ladewig G; Reinhold U; Thirkill CE; Kerber A; Tilgen W; Pföhler C
Br J Dermatol; 2005 May; 152(5):931-8. PubMed ID: 15888149
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of leukocyte-dependent antibody activity in melanoma patients.
Hersey P; Edwards A; Murray E; McCarthy WH; Milton GW
J Natl Cancer Inst; 1983 Jul; 71(1):45-53. PubMed ID: 6575208
[TBL] [Abstract][Full Text] [Related]
11. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study.
Chapman PB; Morrissey DM; Panageas KS; Hamilton WB; Zhan C; Destro AN; Williams L; Israel RJ; Livingston PO
Clin Cancer Res; 2000 Mar; 6(3):874-9. PubMed ID: 10741710
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma.
Visús C; Andres R; Mayordomo JI; Martinez-Lorenzo MJ; Murillo L; Sáez-Gutiérrez B; Diestre C; Marcos I; Astier P; Godino J; Carapeto-Marquez de Prado FJ; Larrad L; Tres A
Melanoma Res; 2007 Apr; 17(2):83-9. PubMed ID: 17496783
[TBL] [Abstract][Full Text] [Related]
13. Circulating immune complexes and tumor cell cytotoxins as prognostic indicators in malignant melanoma: a prospective study of 53 patients.
Rossen RD; Crane MM; Morgan AC; Giannini EH; Giovanella BC; Stehlin JS; Twomey JJ; Hersh EM
Cancer Res; 1983 Jan; 43(1):422-9. PubMed ID: 6600161
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies to human melanoma-associated antigens: an amplified enzyme-linked immunosorbent assay for the detection of antigen, antibody, and immune complexes.
Morgan AC; McIntyre RF
Cancer Res; 1983 Jul; 43(7):3155-9. PubMed ID: 6850625
[TBL] [Abstract][Full Text] [Related]
15. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients.
Haanen JB; Baars A; Gomez R; Weder P; Smits M; de Gruijl TD; von Blomberg BM; Bloemena E; Scheper RJ; van Ham SM; Pinedo HM; van den Eertwegh AJ
Cancer Immunol Immunother; 2006 Apr; 55(4):451-8. PubMed ID: 16034562
[TBL] [Abstract][Full Text] [Related]
16. Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma.
Kiniwa Y; Fujita T; Akada M; Ito K; Shofuda T; Suzuki Y; Yamamoto A; Saida T; Kawakami Y
Cancer Res; 2001 Nov; 61(21):7900-7. PubMed ID: 11691810
[TBL] [Abstract][Full Text] [Related]
17. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
Findeisen P; Zapatka M; Peccerella T; Matzk H; Neumaier M; Schadendorf D; Ugurel S
J Clin Oncol; 2009 May; 27(13):2199-208. PubMed ID: 19307507
[TBL] [Abstract][Full Text] [Related]
18. [Serological analysis of melanoma patients receiving autologous melanoma cell vaccines].
Watanabe T
Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt):261-72. PubMed ID: 6881976
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of melanoma-inhibiting activity do not predict relapse in melanoma patients.
Klimek VM; Williams L; Chapman PB
Cytokines Cell Mol Ther; 2002 Dec; 7(2):71-4. PubMed ID: 12607797
[TBL] [Abstract][Full Text] [Related]
20. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
